Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020115093 - SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE IN A NON-RACEMIC RATIO

Publication Number WO/2020/115093
Publication Date 11.06.2020
International Application No. PCT/EP2019/083594
International Filing Date 04.12.2019
IPC
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07D 207/27 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
18having one double bond between ring members or between a ring member and a non-ring member
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Oxygen or sulfur atoms
262-Pyrrolidones
263with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
27with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
A61K 31/4015 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4015having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61P 25/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
02for peripheral neuropathies
A61P 25/24 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61P 25/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
02for peripheral neuropathies
A61P 25/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 207/27
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
18having one double bond between ring members or between a ring member and a non-ring member
22with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Oxygen or sulfur atoms
262-Pyrrolidones
263with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
27with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Applicants
  • METYS PHARMACEUTICALS AG [CH]/[CH]
Inventors
  • FARINA, Carlo
  • SCHERZ, Michael
  • GHELARDINI, Carla
  • DI CESARE MANNELLI, Lorenzo
Agents
  • VOSSIUS & PARTNER (NO 31)
Priority Data
18210106.304.12.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE IN A NON-RACEMIC RATIO
(FR) COMPOSITIONS SYNERGIQUES COMPRENANT DU (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE ET DU (S)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE DANS UN RAPPORT NON RACÉMIQUE
Abstract
(EN)
The present invention relates to a composition of the enantiomers of 2-(2-oxopyrrolidin-1- yl)butanamide and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from seizure-related disorders, peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.
(FR)
La présente invention concerne une composition d'énantiomères de 2-(2-oxopyrrolidin-1- yl)butanamide et des solvates ou des co-cristaux pharmaceutiquement acceptables de ceux-ci dans un certain rapport, une composition pharmaceutique comprenant ladite composition, son utilisation en tant que médicament et l'utilisation des compositions ou des compositions pharmaceutiques de l'invention dans le traitement et/ou la prévention d'une maladie ou d'un trouble typiquement et préférablement choisi parmi la neuropathie sensorielle périphérique, de préférence la douleur neuropathique périphérique, l'épilepsie, la dépression, ou les troubles cognitifs.
Latest bibliographic data on file with the International Bureau